The rise of DNA methylation and the importance of chromatin on multidrug resistance in cancer

Experimental Cell Research

Volumn 290, Issue 2, 2003, Pages 177-194

  Baker, Emma K ^a   El Osta, Assam ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Cancer; Chemotherapy; Chromatin; Methylation; Multidrug resistance gene 1 (MDR1); Transcriptional regulation; Zinc finger protein (ZFP)

Indexed keywords

ANTHRACYCLINE; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ARABINOSIDE; CYCLOHEXIMIDE; CYTARABINE; DAUNORUBICIN; DNA; DNA BINDING PROTEIN; DNA METHYLTRANSFERASE; EPIRUBICIN; FLUOROURACIL; FORSKOLIN; GLYCOPROTEIN P; HISTONE DEACETYLASE; IDARUBICIN; MEMBRANE PROTEIN; METHYL CPG BINDING PROTEIN; MITOMYCIN C; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN DERIVATIVE; PROTEIN NF R1; PROTEIN NF R2; PROTEIN NF R3; RETINOIC ACID; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; UNINDEXED DRUG; Y BOX BINDING PROTEIN 1; ZEBULARINE; ZINC FINGER PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; CANCER; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL LEVEL; CELL STRAIN HL 60; CELL STRAIN K 562; CHROMATIN; DEMETHYLATION; DNA METHYLATION; DRUG POTENCY; DRUG SENSITIVITY; DRUG TRANSPORT; ENZYME ACTIVITY; GC RICH SEQUENCE; GENE ACTIVATION; GENE AMPLIFICATION; GENE CONTROL; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE INACTIVATION; GENE REPRESSION; GENE SEQUENCE; GENE SILENCING; GENE SWITCHING; GENE TARGETING; GENETIC ORGANIZATION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; LEUKEMIA; MISMATCH REPAIR; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA BINDING; PROTEIN DOMAIN; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN MOTIF; REGULATORY MECHANISM; REVIEW; TRANSACTIVATION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION;

EID: 0142089873     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-4827(03)00342-2     Document Type: Review

References (197)

1. Lehnert M. Clinical multidrug resistance in cancer a multifactorial problem . Eur. J. Cancer. 32A:1996;912-920.
2. Biedler J.L., Riehm H. Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res. 30:1970;1174-1184.
3. Bosch I., Croop J. P-glycoprotein multidrug resistance and cancer. Biochim. Biophys. Acta. 1288:1996;F37-F54.
4. Zaman G.J., Flens M.J., van Leusden M.R., de Haas M., Mulder H.S., Lankelma J., Pinedo H.M., Scheper R.J., Baas F., Broxterman H.J., et al. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc. Natl. Acad. Sci. USA. 91:1994;8822-8826.
5. Scheffer G.L., Wijngaard P.L., Flens M.J., Izquierdo M.A., Slovak M.L., Pinedo H.M., Meijer C.J., Clevers H.C., Scheper R.J. The drug resistance-related protein LRP is the human major vault protein. Nat. Med. 1:1995;578-582.
6. Hochhauser D., Harris A.L. The role of topoisomerase II alpha and beta in drug resistance. Cancer Treat. Rev. 19:1993;181-194.
7. Hao X.Y., Bergh J., Brodin O., Hellman U., Mannervik B. Acquired resistance to cisplatin and doxorubicin in a small cell lung cancer cell line is correlated to elevated expression of glutathione-linked detoxification enzymes. Carcinogenesis. 15:1994;1167-1173.
8. Scotto K.W., Johnson R.A. Transcription of MDR1: a therapeutic target. Mol. Interv. 1:2001;117-125.
9. Labialle S., Gayet L., Marthinet E., Rigal D., Baggetto L.G. Transcriptional regulators of the human multidrug resistance 1 gene recent views . Biochem. Pharmacol. 64:2002;943-948.
10. Ueda K., Yoshida A., Amachi T. Recent progress in P-glycoprotein research. Anticancer Drug Des. 14:1999;115-121.
11. Shtil A.A. Signal transduction pathways and transcriptional mechanisms as targets for prevention of emergence of multidrug resistance in human cancer cells. Curr. Drug Targets. 2:2001;57-77.
12. Fromm M.F. The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv. Drug Deliv. Rev. 54:2002;1295-1310.
13. Fairchild C.R., Ivy S.P., Rushmore T., Lee G., Koo P., Goldsmith M.E., Myers C.E., Farber E., Cowan K.H. Carcinogen-induced mdr overexpression is associated with xenobiotic resistance in rat preneoplastic liver nodules and hepatocellular carcinomas. Proc. Natl. Acad. Sci. USA. 84:1987;7701-7705.
14. Thorgeirsson S.S., Huber B.E., Sorrell S., Fojo A., Pastan I., Gottesman M.M. Expression of the multidrug-resistant gene in hepatocarcinogenesis and regenerating rat liver. Science. 236:1987;1120-1122.
15. Chin K.V., Tanaka S., Darlington G., Pastan I., Gottesman M.M. Heat shock and arsenite increase expression of the multidrug resistance (MDR1) gene in human renal carcinoma cells. J. Biol. Chem. 265:1990;221-226.
16. Mickley L.A., Bates S.E., Richert N.D., Currier S., Tanaka S., Foss F., Rosen N., Fojo A.T. Modulation of the expression of a multidrug resistance gene (mdr-1/P-glycoprotein) by differentiating agents. J. Biol. Chem. 264:1989;18031-18040.
17. Jin S., Scotto K.W. Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y. Mol. Cell Biol. 18:1998;4377-4384.
18. Ueda K., Clark D.P., Chen C.J., Roninson I.B., Gottesman M.M., Pastan I. The human multidrug resistance (MDR1) gene. cDNA cloning and transcription initiation. J. Biol. Chem. 262:1987;505-508.
19. Ueda K., Cardarelli C., Gottesman M.M., Pastan I. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc. Natl. Acad. Sci. USA. 84:1987;3004-3008.
20. Ueda K., Pastan I., Gottesman M.M. Isolation and sequence of the promoter region of the human multidrug-resistance (P-glycoprotein) gene. J. Biol. Chem. 262:1987;17432-174326.
21. Buratowski S., Hahn S., Sharp P.A., Guarente L. Function of a yeast TATA element-binding protein in a mammalian transcription system. Nature. 334:1988;37-42.
22. Sawadogo M., Sentenac A. RNA polymerase B (II) and general transcription factors. Annu. Rev. Biochem. 59:1990;711-754.
23. Corden J., Wasylyk B., Buchwalder A., Sassone-Corsi P., Kedinger C., Chambon P. Promoter sequences of eukaryotic protein-coding genes. Science. 209:1980;1406-1414.
24. Gardiner-Garden M., Frommer M. CpG islands in vertebrate genomes. J. Mol. Biol. 196:1987;261-282.
25. Ishii S., Kadonaga J.T., Tjian R., Brady J.N., Merlino G.T., Pastan I. Binding of the Sp1 transcription factor by the human Harvey ras1 proto-oncogene promoter. Science. 232:1986;1410-1413.
26. Smale S.T., Baltimore D. The "initiator" as a transcription control element. Cell. 57:1989;103-113.
27. Anderson S.J., Chou H.S., Loh D.Y. A conserved sequence in the T-cell receptor beta-chain promoter region. Proc. Natl. Acad. Sci. USA. 85:1988;3551-3554.
28. Means A.L., Farnham P.J. Transcription initiation from the dihydrofolate reductase promoter is positioned by HIP1 binding at the initiation site. Mol. Cell Biol. 10:1990;653-661.
29. Smale S.T., Schmidt M.C., Berk A.J., Baltimore D. Transcriptional activation by Sp1 as directed through TATA or initiator specific requirement for mammalian transcription factor IID . Proc. Natl. Acad. Sci. USA. 87:1990;4509-4513.
30. Madden M.J., Morrow C.S., Nakagawa M., Goldsmith M.E., Fairchild C.R., Cowan K.H. Identification of 5′ and 3′ sequences involved in the regulation of transcription of the human MDR1 gene in vivo. J. Biol. Chem. 268:1993;8290-8297.
31. Cornwell M.M. The human multidrug resistance gene sequences upstream and downstream of the initiation site influence transcription . Cell Growth Differ. 1:1990;607-615.
32. van Groenigen M., Valentijn L.J., Baas F. Identification of a functional initiator sequence in the human MDR1 promoter. Biochim. Biophys. Acta. 1172:1993;138-146.
33. Goldsmith M.E., Madden M.J., Morrow C.S., Cowan K.H. A Y-box consensus sequence is required for basal expression of the human multidrug resistance (MDR1) gene. J. Biol. Chem. 268:1993;5856-5860.
34. Bargou R.C., Jurchott K., Wagener C., Bergmann S., Metzner S., Bommert K., Mapara M.Y., Winzer K.J., Dietel M., Dorken B., Royer H.D. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat. Med. 3:1997;447-450.
35. Ogura M., Takatori T., Sugimoto Y., Tsuruo T. Identification and characterization of three DNA-binding proteins on the promoter of the human MDR1 gene in drug-sensitive and -resistant cells. Jpn J. Cancer Res. 82:1991;1151-1159.
36. Ogura M., Takatori T., Tsuruo T. Purification and characterization of NF-R1 that regulates the expression of the human multidrug resistance (MDR1) gene. Nucleic Acids Res. 20:1992;5811-5817.
37. Gidoni D., Dynan W.S., Tjian R. Multiple specific contacts between a mammalian transcription factor and its cognate promoters. Nature. 312:1984;409-413.
38. Teeter L.D., Eckersberg T., Tsai Y., Kuo M.T. Analysis of the Chinese hamster P-glycoprotein/multidrug resistance gene pgp1 reveals that the AP-1 site is essential for full promoter activity. Cell Growth Differ. 2:1991;429-437.
39. Ackerman S.L., Minden A.G., Williams G.T., Bobonis C., Yeung C.Y. Functional significance of an overlapping consensus binding motif for Sp1 and Zif268 in the murine adenosine deaminase gene promoter. Proc. Natl. Acad. Sci. USA. 88:1991;7523-7527.
40. Parks C.L., Shenk T. The serotonin 1a receptor gene contains a TATA-less promoter that responds to MAZ and Sp1. J. Biol. Chem. 271:1996;4417-4430.
41. Pugh B.F., Tjian R. Mechanism of transcriptional activation by Sp1 evidence for coactivators . Cell. 61:1990;1187-1197.
42. Gill G., Pascal E., Tseng Z.H., Tjian R. A glutamine-rich hydrophobic patch in transcription factor Sp1 contacts the dTAFII110 component of the Drosophila TFIID complex and mediates transcriptional activation. Proc. Natl. Acad. Sci. USA. 91:1994;192-196.
43. Borellini F., Aquino A., Josephs S.F., Glazer R.I. Increased expression and DNA-binding activity of transcription factor Sp1 in doxorubicin-resistant HL-60 leukemia cells. Mol. Cell Biol. 10:1990;5541-5547.
44. Cornwell M.M., Smith D.E. SP1 activates the MDR1 promoter through one of two distinct G-rich regions that modulate promoter activity. J. Biol. Chem. 268:1993;19505-19511.
45. Yu L., Wu Q., Yang C.P., Horwitz S.B. Coordination of transcription factors, NF-Y and C/EBP beta, in the regulation of the MDR1b promoter. Cell Growth Differ. 6:1995;1505-1512.
46. Combates N.J., Rzepka R.W., Chen Y.N., Cohen D. NF-IL6, a member of the C/EBP family of transcription factors, binds and trans-activates the human MDR1 gene promoter. J. Biol. Chem. 269:1994;29715-29719.
47. Morrow C.S., Nakagawa M., Goldsmith M.E., Madden M.J., Cowan K.H. Reversible transcriptional activation of MDR1 by sodium butyrate treatment of human colon cancer cells. J. Biol. Chem. 269:1994;10739-10746.
48. Graessmann A., Graessmann M. DNA methylation, chromatin structure and regulation of Herpes simplex virus tk gene expression. Gene. 74:1988;135-137.
49. Buschhausen G., Wittig B., Graessmann M., Graessmann A. Chromatin structure is required to block transcription of the methylated herpes simplex virus thymidine kinase gene. Proc. Natl. Acad. Sci. USA. 84:1987;1177-1181.
50. Kass S.U., Landsberger N., Wolffe A.P. DNA methylation directs a time-dependent repression of transcription initiation. Curr. Biol. 7:1997;157-165.
51. Kass S.U., Pruss D., Wolffe A.P. How does DNA methylation repress transcription? Trends Genet. 13:1997;444-449.
52. Meehan R.R., Lewis J.D., McKay S., Kleiner E.L., Bird A.P. Identification of a mammalian protein that binds specifically to DNA containing methylated CpGs. Cell. 58:1989;499-507.
53. Lewis J.D., Meehan R.R., Henzel W.J., Maurer-Fogy I., Jeppesen P., Klein F., Bird A. Purification, sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA. Cell. 69:1992;905-914.
54. Hendrich B., Bird A. Identification and characterization of a family of mammalian methyl-CpG binding proteins. Mol. Cell Biol. 18:1998;6538-6547.
55. Ng H.H., Jeppesen P., Bird A. Active repression of methylated genes by the chromosomal protein MBD1. Mol. Cell Biol. 20:2000;1394-1406.
56. Ng H.H., Zhang Y., Hendrich B., Johnson C.A., Turner B.M., Erdjument-Bromage H., Tempst P., Reinberg D., Bird A. MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex. Nat. Genet. 23:1999;58-61.
57. Zhang Y., Ng H.H., Erdjument-Bromage H., Tempst P., Bird A., Reinberg D. Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev. 13:1999;1924-1935.
58. Wade P.A., Gegonne A., Jones P.L., Ballestar E., Aubry F., Wolffe A.P. Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation. Nat. Genet. 23:1999;62-66.
59. Hendrich B., Guy J., Ramsahoye B., Wilson V.A., Bird A. Closely related proteins MBD2 and MBD3 play distinctive but interacting roles in mouse development. Genes Dev. 15:2001;710-723.
60. El-Osta A., Kantharidis P., Zalcberg J.R., Wolffe A.P. Precipitous release of methyl-CpG binding protein 2 and histone deacetylase 1 from the methylated human multidrug resistance gene (MDR1) on activation. Mol. Cell Biol. 22:2002;1844-1857.
61. Roder K., Latasa M.J., Sul H.S. Silencing of the mouse H-rev107 gene encoding a class II tumor suppressor by CpG methylation. J. Biol. Chem. 277:2002;30543-30550.
62. Gregory R.I., Randall T.E., Johnson C.A., Khosla S., Hatada I., O'Neill L.P., Turner B.M., Feil R. DNA methylation is linked to deacetylation of histone H3, but not H4, on the imprinted genes Snrpn and U2af1-rs1. Mol. Cell Biol. 21:2001;5426-5436.
63. Rietveld L.E., Caldenhoven E., Stunnenberg H.G. In vivo repression of an erythroid-specific gene by distinct corepressor complexes. Embo. J. 21:2002;1389-1397.
64. Drewell R.A., Goddard C.J., Thomas J.O., Surani M.A. Methylation-dependent silencing at the H19 imprinting control region by MeCP2. Nucleic Acids Res. 30:2002;1139-1144.
65. Yu F., Zingler N., Schumann G., Stratling W.H. Methyl-CpG-binding protein 2 represses LINE-1 expression and retrotransposition but not Alu transcription. Nucleic Acids Res. 29:2001;4493-4501.
66. Meehan R.R., Lewis J.D., Bird A.P. Characterization of MeCP2, a vertebrate DNA binding protein with affinity for methylated DNA. Nucleic Acids Res. 20:1992;5085-5092.
67. Nan X., Meehan R.R., Bird A. Dissection of the methyl-CpG binding domain from the chromosomal protein MeCP2. Nucleic Acids Res. 21:1993;4886-4892.
68. Nan X., Tate P., Li E., Bird A. DNA methylation specifies chromosomal localization of MeCP2. Mol. Cell Biol. 16:1996;414-421.
69. Nan X., Campoy F.J., Bird A. MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell. 88:1997;471-481.
70. Nan X., Ng H.H., Johnson C.A., Laherty C.D., Turner B.M., Eisenman R.N., Bird A. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature. 393:1998;386-389.
71. Jones P.L., Veenstra G.J., Wade P.A., Vermaak D., Kass S.U., Landsberger N., Strouboulis J., Wolffe A.P. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat. Genet. 19:1998;187-191.
72. Lorincz M.C., Schubeler D., Groudine M. Methylation-mediated proviral silencing is associated with MeCP2 recruitment and localized histone H3 deacetylation. Mol. Cell Biol. 21:2001;7913-7922.
73. Fuks F., Hurd P.J., Wolf D., Nan X., Bird A.P., Kouzarides T. The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J. Biol. Chem. 278:2003;4035-4040.
74. Fujita N., Shimotake N., Ohki I., Chiba T., Saya H., Shirakawa M., Nakao M. Mechanism of transcriptional regulation by methyl-CpG binding protein MBD1. Mol. Cell Biol. 20:2000;5107-5118.
75. Fujita N., Takebayashi S., Okumura K., Kudo S., Chiba T., Saya H., Nakao M. Methylation-mediated transcriptional silencing in euchromatin by methyl-CpG binding protein MBD1 isoforms. Mol. Cell Biol. 19:1999;6415-6426.
76. Brackertz M., Boeke J., Zhang R., Renkawitz R. Two highly related p66 proteins comprise a new family of potent transcriptional repressors interacting with MBD2 and MBD3. J. Biol. Chem. 277:2002;40958-40966.
77. Bakker J., Lin X., Nelson W.G. Methyl-CpG binding domain protein 2 represses transcription from hypermethylated pi-class glutathione S-transferase gene promoters in hepatocellular carcinoma cells. J. Biol. Chem. 277:2002;22573-22580.
78. Sekimata M., Takahashi A., Murakami-Sekimata A., Homma Y. Involvement of a novel zinc finger protein, MIZF, in transcriptional repression by interacting with a methyl-CpG-binding protein, MBD2. J. Biol. Chem. 276:2001;42632-42638.
79. Singal R., van Wert J., Bashambu M. Cytosine methylation represses glutathione S-transferase P1 (GSTP1) gene expression in human prostate cancer cells. Cancer Res. 61:2001;4820-4826.
80. Magdinier F., Wolffe A.P. Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia. Proc. Natl. Acad. Sci. USA. 98:2001;4990-4995.
81. Feng Q., Zhang Y. The MeCP1 complex represses transcription through preferential binding, remodeling, and deacetylating methylated nucleosomes. Genes Dev. 15:2001;827-832.
82. Boeke J., Ammerpohl O., Kegel S., Moehren U., Renkawitz R. The minimal repression domain of MBD2b overlaps with the methyl-CpG-binding domain and binds directly to Sin3A. J. Biol. Chem. 275:2000;34963-34967.
83. Mutskov V.J., Farrell C.M., Wade P.A., Wolffe A.P., Felsenfeld G. The barrier function of an insulator couples high histone acetylation levels with specific protection of promoter DNA from methylation. Genes Dev. 16:2002;1540-1554.
84. Feng Q., Cao R., Xia L., Erdjument-Bromage H., Tempst P., Zhang Y. Identification and functional characterization of the p66/p68 components of the MeCP1 complex. Mol. Cell. Biol. 22:2002;536-546.
85. Millar C.B., Guy J., Sansom O.J., Selfridge J., MacDougall E., Hendrich B., Keightley P.D., Bishop S.M., Clarke A.R., Bird A. Enhanced CpG mutability and tumorigenesis in MBD4-deficient mice. Science. 297:2002;403-405.
86. Zhu B., Zheng Y., Angliker H., Schwarz S., Thiry S., Siegmann M., Jost J.P. 5-Methylcytosine DNA glycosylase activity is also present in the human MBD4 (G/T mismatch glycosylase) and in a related avian sequence. Nucleic Acids Res. 28:2000;4157-4165.
87. Hendrich B., Hardeland U., Ng H.H., Jiricny J., Bird A. The thymine glycosylase MBD4 can bind to the product of deamination at methylated CpG sites. Nature. 401:1999;301-304.
88. Bellacosa A., Cicchillitti L., Schepis F., Riccio A., Yeung A.T., Matsumoto Y., Golemis E.A., Genuardi M., Neri G. MED1, a novel human methyl-CpG-binding endonuclease, interacts with DNA mismatch repair protein MLH1. Proc. Natl. Acad. Sci. USA. 96:1999;3969-3974.
89. Petronzelli F., Riccio A., Markham G.D., Seeholzer S.H., Stoerker J., Genuardi M., Yeung A.T., Matsumoto Y., Bellacosa A. Biphasic kinetics of the human DNA repair protein MED1 (MBD4), a mismatch-specific DNA N-glycosylase. J. Biol. Chem. 275:2000;32422-32429.
90. Miller O.J., Schnedl W., Allen J., Erlanger B.F. 5-Methylcytosine localised in mammalian constitutive heterochromatin. Nature. 251:1974;636-637.
91. Walia H., Chen H.Y., Sun J.M., Holth L.T., Davie J.R. Histone acetylation is required to maintain the unfolded nucleosome structure associated with transcribing DNA. J. Biol. Chem. 273:1998;14516-14522.
92. Lachner M., O'Sullivan R.J., Jenuwein T. An epigenetic road map for histone lysine methylation. J. Cell Sci. 116:2003;2117-2124.
93. Graff J.R., Herman J.G., Lapidus R.G., Chopra H., Xu R., Jarrard D.F., Isaacs W.B., Pitha P.M., Davidson N.E., Baylin S.B. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res. 55:1995;5195-5199.
94. Desiderato L., Davey M.W., Piper A.A. Demethylation of the human MDR1 5′ region accompanies activation of P-glycoprotein expression in a HL60 multidrug resistant subline. Somat. Cell Mol. Genet. 23:1997;391-400.
95. Kusaba H., Nakayama M., Harada T., Torigoe K., Green E.D., Scherer S.W., Kohno K., Kuwano M., Wada M. Maintenance of hypomethylation status and preferential expression of exogenous human MDR1/PGY1 gene in mouse L cells by YAC mediated transfer. Somat. Cell Mol. Genet. 23:1997;259-274.
96. Kantharidis P., El-Osta A., deSilva M., Wall D.M., Hu X.F., Slater A., Nadalin G., Parkin J.D., Zalcberg J.R. Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance. Clin. Cancer Res. 3:1997;2025-2032.
97. Jones P.A. Altering gene expression with 5-azacytidine. Cell. 40:1985;485-486.
98. Cedar H. DNA methylation and gene activity. Cell. 53:1988;3-4.
99. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3:2002;415-428.
100. Creusol F., Acs G., Christman J.K. Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2′-deoxycytidine. J. Biol. Chem. 257:1982;2041-2048.
101. Christman J.K., Schneiderman N., Acs G. Formation of highly stable complexes between 5-azacytosine-substituted DNA and specific non-histone nuclear proteins. Implications for 5-azacytidine-mediated effects on DNA methylation and gene expression. J. Biol. Chem. 260:1985;4059-4068.
102. Zhou L., Cheng X., Connolly B., Dickman M., Hurd P., Hornby D. Zebularine A novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases . J. Mol. Biol. 321:2002;591.
103. Fuks F., Burgers W.A., Brehm A., Hughes-Davies L., Kouzarides T. DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat. Genet. 24:2000;88-91.
104. Fuks F., Burgers W.A., Godin N., Kasai M., Kouzarides T. Dnmt3a binds deacetylases and is recruited by a sequence-specific repressor to silence transcription. Embo. J. 20:2001;2536-2544.
105. Rountree M.R., Bachman K.E., Baylin S.B. DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat. Genet. 25:2000;269-277.
106. Robertson K.D., Ait-Si-Ali S., Yokochi T., Wade P.A., Jones P.L., Wolffe A.P. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat. Genet. 25:2000;338-342.
107. Aapola U., Liiv I., Peterson P. Imprinting regulator DNMT3L is a transcriptional repressor associated with histone deacetylase activity. Nucleic Acids Res. 30:2002;3602-3608.
108. Deplus R., Brenner C., Burgers W.A., Putmans P., Kouzarides T., de Launoit Y., Fuks F. Dnmt3L is a transcriptional repressor that recruits histone deacetylase. Nucleic Acids Res. 30:2002;3831-3838.
109. Yang X., Phillips D.L., Ferguson A.T., Nelson W.G., Herman J.G., Davidson N.E. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res. 61:2001;7025-7029.
110. El-Osta A. FMR1 silencing and the signals to chromatin a unified model of transcriptional regulation . Biochem Biophys Res Commun. 295:2002;575-581.
111. Bird A.P., Wolffe A.P. Methylation-induced repression-belts, braces, and chromatin. Cell. 99:1999;451-454.
112. Cameron E.E., Bachman K.E., Myohanen S., Herman J.G., Baylin S.B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 21:1999;103-107.
113. Coffee B., Zhang F., Warren S.T., Reines D. Acetylated histones are associated with FMR1 in normal but not fragile X-syndrome cells. Nat. Genet. 22:1999;98-101.
114. Shibata H., Kanamaru R., Sato T., Ishioka C., Konishi Y., Ishikawa A., Wakui A., Tsuruo T. Increase in the level of P-glycoprotein mRNA expression in multidrug-resistant K562 cell lines treated with sodium butyrate is not accompanied with erythroid differentiation. Jpn J. Cancer Res. 81:1990;1214-1217.
115. Suzuki H., Gabrielson E., Chen W., Anbazhagan R., van Engeland M., Weijenberg M.P., Herman J.G., Baylin S.B. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat. Genet. 31:2002;141-149.
116. Nakayama M., Wada M., Harada T., Nagayama J., Kusaba H., Ohshima K., Kozuru M., Komatsu H., Ueda R., Kuwano M. Hypomethylation status of CpG sites at the promoter region and overexpression of the human MDR1 gene in acute myeloid leukemias. Blood. 92:1998;4296-4307.
117. Estey E.H. Treatment of acute myelogenous leukemia and myelodysplastic syndromes. Semin. Hematol. 32:1995;132-151.
118. Rothenberg M.L., Mickley L.A., Cole D.E., Balis F.M., Tsuruo T., Poplack D.G., Fojo A.T. Expression of the mdr-1/P-170 gene in patients with acute lymphoblastic leukemia. Blood. 74:1989;1388-1395.
119. Hiddemann W., Martin W.R., Sauerland C.M., Heinecke A., Buchner T. Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized first line therapy . Leukemia. 4:1990;184-188.
120. Marie J.P., Zittoun R., Sikic B.I. Multidrug resistance (MDR1) gene expression in adult acute leukemias correlations with treatment outcome and in vitro drug sensitivity . Blood. 78:1991;586-592.
121. Kuwazuru Y., Yoshimura A., Hanada S., Utsunomiya A., Makino T., Ishibashi K., Kodama M., Iwahashi M., Arima T., Akiyama S. Expression of the multidrug transporter, P-glycoprotein, in acute leukemia cells and correlation to clinical drug resistance. Cancer. 66:1990;868-873.
122. Hu X.F., Slater A., Kantharidis P., Rischin D., Juneja S., Rossi R., Lee G., Parkin J.D., Zalcberg J.R. Altered multidrug resistance phenotype caused by anthracycline analogues and cytosine arabinoside in myeloid leukemia. Blood. 93:1999;4086-4095.
123. Toyota M., Kopecky K.J., Toyota M.O., Jair K.W., Willman C.L., Issa J.P. Methylation profiling in acute myeloid leukemia. Blood. 97:2001;2823-2829.
124. Wolffe A.P., Jones P.L., Wade P.A. DNA demethylation. Proc. Natl. Acad. Sci. USA. 96:1999;5894-5896.
125. Bhattacharya S.K., Ramchandani S., Cervoni N., Szyf M. A mammalian protein with specific demethylase activity for mCpG DNA. Nature. 397:1999;579-583.
126. Oswald J., Engemann S., Lane N., Mayer W., Olek A., Fundele R., Dean W., Reik W., Walter J. Active demethylation of the paternal genome in the mouse zygote. Curr. Biol. 10:2000;475-478.
127. Reik W., Walter J. Imprinting mechanisms in mammals. Curr. Opin. Genet. Dev. 8:1998;154-164.
128. Detich N., Theberge J., Szyf M. Promoter-specific Activation and Demethylation by MBD2/Demethylase. J. Biol. Chem. 277:2002;35791-35794.
129. Baylin S., Bestor T.H. Altered methylation patterns in cancer cell genomes cause or consequence? Cancer Cell. 1:2002;299-305.
130. Rountree M.R., Bachman K.E., Herman J.G., Baylin S.B. DNA methylation, chromatin inheritance, and cancer. Oncogene. 20:2001;3156-3165.
131. Ponder B.A. Cancer genetics. Nature. 411:2001;336-341.
132. Hanada M., Delia D., Aiello A., Stadtmauer E., Reed J.C. bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood. 82:1993;1820-1828.
133. Vachtenheim J., Horakova I., Novotna H. Hypomethylation of CCGG sites in the 3′ region of H-ras protooncogene is frequent and is associated with H-ras allele loss in non-small cell lung cancer. Cancer Res. 54:1994;1145-1148.
134. Ono T., Yamamoto S., Kurishita A., Yamamoto K., Yamamoto Y., Ujeno Y., Sagisaka K., Fukui Y., Miyamoto M., Tawa R., et al. Comparison of age-associated changes of c-myc gene methylation in liver between man and mouse. Mutat. Res. 237:1990;239-246.
135. Razin A., Riggs A.D. DNA methylation and gene function. Science. 210:1980;604-610.
136. Kusaba H., Nakayama M., Harada T., Nomoto M., Kohno K., Kuwano M., Wada M. Association of 5′ CpG demethylation and altered chromatin structure in the promoter region with transcriptional activation of the multidrug resistance 1 gene in human cancer cells. Eur. J. Biochem. 262:1999;924-932.
137. Garcia-Manero G., Daniel J., Smith T.L., Kornblau S.M., Lee M.S., Kantarjian H.M., Issa J.P. DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clin Cancer Res. 8:2002;2217-2224.
138. Garcia-Manero G., Bueso-Ramos C., Daniel J., Williamson J., Kantarjian H.M., Issa J.P. DNA methylation patterns at relapse in adult acute lymphocytic leukemia. Clin. Cancer Res. 8:2002;1897-1903.
139. Tada Y., Wada M., Kuroiwa K., Kinugawa N., Harada T., Nagayama J., Nakagawa M., Naito S., Kuwano M. MDR1 gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment. Clin. Cancer Res. 6:2000;4618-4627.
140. Shannon B.A., Iacopetta B.J. Methylation of the hMLH1, p16, an MDR1 genes in colorectal carcinoma associations with clinicopathological features . Cancer Lett. 167:2001;91-97.
141. Hsieh C.L. Evidence that protein binding specifies sites of DNA demethylation. Mol. Cell Biol. 19:1999;46-56.
142. Vairapandi M., Duker N.J. Enzymic removal of 5-methylcytosine from DNA by a human DNA-glycosylase. Nucleic Acids Res. 21:1993;5323-5327.
143. Weiss A., Keshet I., Razin A., Cedar H. DNA demethylation in vitro involvement of RNA . Cell. 86:1996;709-718.
144. Walsh C.P., Bestor T.H. Cytosine methylation and mammalian development. Genes Dev. 13:1999;26-34.
145. Jones P.A., Laird P.W. Cancer epigenetics comes of age. Nat. Genet. 21:1999;163-167.
146. Boeke J., Ammerpohl O., Kegel S., Moehren U., Renkawitz R. The minimal repression domain of MBD2b overlaps with the methyl-CpG-binding domain and binds directly to Sin3A. J. Biol. Chem. 275:2000;34963-34967.
147. Smith S.S. Gilbert's conjecture the search for DNA (cytosine-5) demethylases and the emergence of new functions for eukaryotic DNA (cytosine-5) methyltransferases . J. Mol. Biol. 302:2000;1-7.
148. Jost J.P., Siegmann M., Sun L., Leung R. Mechanisms of DNA demethylation in chicken embryos. Purification and properties of a 5-methylcytosine-DNA glycosylase. J. Biol. Chem. 270:1995;9734-9739.
149. Fremont M., Siegmann M., Gaulis S., Matthies R., Hess D., Jost J.P. Demethylation of DNA by purified chick embryo 5-methylcytosine-DNA glycosylase requires both protein and RNA. Nucleic Acids Res. 25:1997;2375-2380.
150. Jost J.P., Fremont M., Siegmann M., Hofsteenge J. The RNA moiety of chick embryo 5-methylcytosine-DNA glycosylase targets DNA demethylation. Nucleic Acids Res. 25:1997;4545-4550.
151. Zhu B., Zheng Y., Hess D., Angliker H., Schwarz S., Siegmann M., Thiry S., Jost J.P. 5-methylcytosine-DNA glycosylase activity is present in a cloned G/T mismatch DNA glycosylase associated with the chicken embryo DNA demethylation complex. Proc. Natl. Acad. Sci. USA. 97:2000;5135-5139.
152. Hu X.F., Slater A., Wall D.M., Kantharidis P., Parkin J.D., Cowman A., Zalcberg J.R. Rapid up-regulation on MDR1 expression by anthracyclines in a classical multidrug-resistant cell line. Br. J. Cancer. 71:1995;931-936.
153. Kohno K., Sato S., Takano H., Matsuo K., Kuwano M. The direct activation of human multidrug resistance gene (MDR1) by anticancer agents. Biochem. Biophys. Res. Commun. 165:1989;1415-1421.
154. Hu X.F., Slater A., Rischin D., Kantharidis P., Parkin J.D., Zalcberg J. Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line. Br. J. Cancer. 79:1999;831-837.
155. Chin K.V., Chauhan S.S., Pastan I., Gottesman M.M. Regulation of mdr RNA levels in response to cytotoxic drugs in rodent cells. Cell Growth Differ. 1:1990;361-365.
156. Fardel O., Lecureur V., Daval S., Corlu A., Guillouzo A. Up-regulation of P-glycoprotein expression in rat liver cells by acute doxorubicin treatment. Eur. J. Biochem. 246:1997;186-192.
157. Abolhoda A., Wilson A.E., Ross H., Danenberg P.V., Burt M., Scotto K.W. Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin. Cancer Res. 5:1999;3352-3356.
158. Sakashita K., Koike K., Kinoshita T., Shiohara M., Kamijo T., Taniguchi S., Kubota T. Dynamic DNA methylation change in the CpG island region of p15 during human mycloid development. J. Clin. Invest. 108:2001;1195-1204.
159. Esteller M. CpG island hypermethylation and tumor suppressor genes a booming present, a brighter future . Oncogene. 21:2002;5427-5440.
160. Cameron E.E., Baylin S.B., Herman J.G. p15(INK4B) CpG island methylation in primary acute leukemia is heterogeneous and suggests density as a critical factor for transcriptional silencing. Blood. 94:1999;2445-2451.
161. Ren D., Collingwood T.N., Rebar E.J., Wolffe A.P., Camp H.S. PPARgamma knockdown by engineered transcription factors exogenous PPARgamma2 but not PPARgamma1 reactivates adipogenesis . Genes Dev. 16:2002;27-32.
162. Kang J.S., Kim J.S. Zinc finger proteins as designer transcription factors. J. Biol. Chem. 275:2000;8742-8748.
163. Beerli R.R., Dreier B., Barbas C.F. 3rd. Positive and negative regulation of endogenous genes by designed transcription factors. Proc. Natl. Acad. Sci. USA. 97:2000;1495-1500.
164. Klug A., Rhodes D. Zinc fingers a novel protein fold for nucleic acid recognition . Cold Spring Harb. Symp. Quant. Biol. 52:1987;473-482.
165. Reik A., Gregory P.D., Urnov F.D. Biotechnologies and therapeutics chromatin as a target . Curr. Opin. Genet. Dev. 12:2002;233-242.
166. Pabo C.O., Peisach E., Grant R.A. Design and selection of novel Cys2His2 zinc finger proteins. Annu. Rev. Biochem. 70:2001;313-340.
167. Frankel A.D., Berg J.M., Pabo C.O. Metal-dependent folding of a single zinc finger from transcription factor IIIA. Proc. Natl. Acad. Sci. USA. 84:1987;4841-4845.
168. Choo Y., Sanchez-Garcia I., Klug A. In vivo repression by a site-specific DNA-binding protein designed against an oncogenic sequence. Nature. 372:1994;642-645.
169. Greisman H.A., Pabo C.O. A general strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites. Science. 275:1997;657-661.
170. Liu P.Q., Rebar E.J., Zhang L., Liu Q., Jamieson A.C., Liang Y., Qi H.,
171. Xu D., Ye D., Fisher M., Juliano R.L. Selective inhibition of P-glycoprotein expression in multidrug-resistant tumor cells by a designed transcriptional regulator. J. Pharmacol. Exp. Ther. 302:2002;963-971.
172. Bartsevich V.V., Juliano R.L. Regulation of thMDR1 gene by transcriptional repressors selected using peptide combinatorial libraries. Mol. Pharmacol. 58:2000;1-10.
173. Wolfe S.A., Greisman H.A., Ramm E.I., Pabo C.O. Analysis of zinc fingers optimized via phage display evaluating the utility of a recognition code . J. Mol. Biol. 285:1999;1917-1934.
174. Bellefroid E.J., Poncelet D.A., Lecocq P.J., Revelant O., Martial J.A. The evolutionarily conserved Kruppel-associated box domain defines a subfamily of eukaryotic multifingered proteins. Proc. Natl. Acad. Sci. USA. 88:1991;3608-3612.
175. Margolin J.F., Friedman J.R., Meyer W.K., Vissing H., Thiesen H.J., Rauscher F.J. 3rd. Kruppel-associated boxes are potent transcriptional repression domains. Proc. Natl. Acad. Sci. USA. 91:1994;4509-4513.
176. Moosmann P., Georgiev O., Le Douarin B., Bourquin J.P., Schaffner W. Transcriptional repression by RING finger protein TIF1 beta that interacts with the KRAB repressor domain of KOX1. Nucleic Acids Res. 24:1996;4859-4867.
177. Moosmann P., Georgiev O., Thiesen H.J., Hagmann M., Schaffner W. Silencing of RNA polymerases II and III-dependent transcription by the KRAB protein domain of KOX1, a Kruppel-type zinc finger factor. Biol. Chem. 378:1997;669-677.
178. Schultz D.C., Friedman J.R., Rauscher F.J. 3rd. Targeting histone deacetylase complexes via KRAB-zinc finger proteins the PHD and bromodomains of KAP-1 form a cooperative unit that recruits a novel isoform of the Mi-2alpha subunit of NuRD . Genes Dev. 15:2001;428-443.
179. El-Osta A. On the use of DNA methylation inhibitors and the reversal of transcriptional silencing. Blood. 101:2003;1656. author reply 1657-1658.
180. Carpinteiro A., Peinert S., Ostertag W., Zander A.R., Hossfeld D.K., Kuhlcke K., Eckert H.G., Baum C., Hegewisch-Becker S. Genetic protection of repopulating hematopoietic cells with an improved MDR1-retrovirus allows administration of intensified chemotherapy following stem cell transplantation in mice. Int. J. Cancer. 98:2002;785-792.
181. Schiedlmeier B., Schilz A.J., Kuhlcke K., Laufs S., Baum C., Zeller W.J., Eckert H.G., Fruehauf S. Multidrug resistance 1 gene transfer can confer chemoprotection to human peripheral blood progenitor cells engrafted in immunodeficient mice. Hum. Gene. Ther. 13:2002;233-242.
182. Lois C., Hong E.J., Pease S., Brown E.J., Baltimore D. Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science. 295:2002;868-872.
183. Ramezani A., Hawley T.S., Hawley R.G. Performance- and safety-enhanced lentiviral vectors containing the human interferon-{beta} scaffold attachment region and the chicken {beta}-globin insulator. Blood. 101:2003;4717-4724.
184. Hill B.T., Deuchars K., Hosking L.K., Ling V., Whelan R.D. Overexpression of P-glycoprotein in mammalian tumor cell lines after fractionated X irradiation in vitro. J. Natl. Cancer Inst. 82:1990;607-612.
185. Bates S.E., Currier S.J., Alvarez M., Fojo A.T. Modulation of P-glycoprotein phosphorylation and drug transport by sodium butyrate. Biochemistry, 31:1992;6366-6372.
186. Gant T.W., Silverman J.A., Thorgeirsson S.S. Regulation of P-glycoprotein gene expression in hepatocyte cultures and liver cell lines by a trans-acting transcriptional repressor. Nucleic Acids Res. 20:1992;2841-2846.
187. Chin K.V., Ueda K., Pastan I., Gottesman M.M. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science. 255:1992;459-462.
188. Miyazaki M., Kohno K., Uchiumi T., Tanimura H., Matsuo K., Nasu M., Kuwano M. Activation of human multidrug resistance-1 gene promoter in response to heat shock stress. Biochem. Biophys. Res. Commun. 187:1992;677-684.
189. Chaudhary P.M., Roninson I.B. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J. Natl. Cancer Inst. 85:1993;632-639.
190. Cornwell M.M., Smith D.E. A signal transduction pathway for activation of the MDR1 promoter involves the proto-oncogene c-raf kinase. J. Biol. Chem. 268:1993;15347-15350.
191. Ferrandis E., Benard J. Activation of the human MDR1 gene promoter in differentiated neuroblasts. Int J Cancer. 54:1993;987-991.
192. Kramer R., Weber T.K., Arceci R., Morse B., Simpson H., Steele G.D. Jr., Summerhayes I.C. Modulation of mdr-1 expression by a H-ras oncogene in a human colon carcinoma cell line. Int. J. Cancer. 54:1993;275-281.
193. Uchiumi T., Kohno K., Tanimura H., Hidaka K., Asakuno K., Abe H., Uchida Y., Kuwano M. Involvement of protein kinase in environmental stress-induced activation of human multidrug resistance 1 (MDR1) gene promoter. FEBS Lett. 326:1993;11-16.
194. Uchiumi T., Kohno K., Tanimura H., Matsuo K., Sato S., Uchida Y., Kuwano M. Enhanced expression of the human multidrug resistance 1 gene in response to UV light irradiation. Cell Growth Differ. 4:1993;147-157.
195. Zastawny R.L., Salvino R., Chen J., Benchimol S., Ling V. The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53. Oncogene. 8:1993;1529-1535.
196. McCoy C., Smith D.E., Cornwell M.M. 12-O-tetradecanoylphorbol-13-acetate activation of the MDR1 promoter is mediated by EGR1. Mol. Cell Biol. 15:1995;6100-6108.
197. Combates N.J., Kwon P.O., Rzepka R.W., Cohen D. Involvement of the transcription factor NF-IL6 in phorbol ester induction of P-glycoprotein in U937 cells. Cell Growth Differ. 8:1997;213-219.